Skip to Content

Succimer Dosage

Medically reviewed by Drugs.com. Last updated on Oct 30, 2020.

Applies to the following strengths: 100 mg

Usual Pediatric Dose for Lead Poisoning - Severe

1 year or older:
Initial dose: 10 mg/kg or 350 mg/m2 orally every 8 hours for five days
Maintenance dose: 10 mg/kg or 350 mg/m2 orally every 12 hours for 14 days

8 kg to 15 kg:
Initial dose: 100 mg orally every 8 hours for five days
Maintenance dose: 100 mg orally every 12 hours for 14 days

16 kg to 23 kg:
Initial dose: 200 mg orally every 8 hours for five days
Maintenance dose: 200 mg orally every 12 hours for 14 days

24 kg to 34 kg:
Initial dose: 300 mg orally every 8 hours for five days
Maintenance dose: 300 mg orally every 12 hours for 14 days

35 kg to 44 kg:
Initial dose: 400 mg orally every 8 hours for five days
Maintenance dose: 400 mg orally every 12 hours for 14 days

45 kg or greater:
Initial dose: 500 mg orally every 8 hours for five days
Maintenance dose: 500 mg orally every 12 hours for 14 days

Comments:
-Do not use for prophylaxis of lead poisoning in a lead-containing environment.
-Always identify and remove the source of the lead exposure.
-May repeat courses if indicated by weekly blood lead concentration levels, with a minimum of two weeks between courses unless blood lead levels necessitate more rapid treatment.

Use: Treatment of lead poisoning in pediatric patients with blood lead levels above 45 mcg/dL

Renal Dose Adjustments

Use with caution.

Liver Dose Adjustments

Data not available
-Close monitoring is recommended for patients with a history of liver disease.

Dose Adjustments

Neutropenia:
-Withhold or discontinue if absolute neutrophil count (ANC) falls below 1200/mcL; follow patient closely until recovery of ANC to over 1500/mcL or the patients baseline level.
-Due to limited experience with re-exposure in patients who experienced neutropenia, use this drug only if therapy clearly outweighs the risk of another neutropenic episode and monitor the patient closely.

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to the drug

Safety and efficacy have not been established in patients younger than 12 months.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available
-Limited data suggests succimer is dialyzable, but not the lead chelates.

Other Comments

Administration advice:
-The capsule may be opened, and the contents administered on a small amount of food for those unable to swallow the capsules.

Monitoring:
-Neutropenia has been reported with drugs in this chemical class.
Recommendations:
-A complete blood count, including white blood cell differential and direct platelet counts should be performed prior to therapy and weekly during treatment, also if infection is suspected.
-Withhold or discontinue if absolute neutrophil count (ANC) falls below 1200/mcL; follow patient closely until recovery of ANC to over 1500/mcL or the patients baseline level.
-Due to limited experience with re-exposure in patients who experienced neutropenia, use this drug only if therapy clearly outweighs the risk of another neutropenic episode and monitor the patient closely.

Patient advice:
-Advise patients to report signs of infection promptly.
-Advise patients to maintain adequate fluid intake.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about succimer

Consumer resources

Other brands: Chemet

Professional resources

Related treatment guides